Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA
Scientist and biotech entrepreneur Michael Gilman is joining the $100 million-plus club with his startup Arrakis. And he’s all-in as the developer — one of the more prominent players in a pack of biotechs looking to use small molecules to drug RNA — sets out to transition from platform building to pipeline construction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.